Core Viewpoint - Affimed N.V. has filed for insolvency proceedings due to insufficient funds to continue operations and has determined that it is overindebted [1][2][3][4]. Group 1: Company Situation - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer [5]. - The company has been unable to raise sufficient capital despite ongoing fundraising efforts, leading to substantial doubt about its ability to continue as a going concern [2][3]. - The management board has concluded that both Affimed N.V. and its subsidiary Affimed GmbH are overindebted and must file for insolvency under German law [3][4]. Group 2: Insolvency Proceedings - On May 13, 2025, the management board filed for ordinary insolvency proceedings for both Affimed N.V. and Affimed GmbH with the local court in Mannheim, Germany [4]. - The outcome of the insolvency proceedings remains uncertain, including whether the companies will emerge as going concerns [4]. - The filing for insolvency will lead to the suspension and subsequent delisting of the company's common shares from The Nasdaq Global Market [4].

Core Insights - Affimed N.V. announced that an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE) acimtamig in combination with AlloNK (AB-101) has been accepted for oral presentation at the ASCO Annual Meeting scheduled for May 30 – June 3, 2025 [1] - Two abstracts on AFM24 in combination with atezolizumab for non-small cell lung cancer (NSCLC) have also been accepted for poster presentations at the same event [1] Presentation Details - The oral presentation will cover the completed dose-finding part of the phase 2 study of acimtamig in combination with AlloNK for relapsed or refractory classical Hodgkin lymphoma, scheduled for May 30, 2025 [2] - The poster presentations will include initial results from a phase 2a study of AFM24 in combination with atezolizumab for advanced/metastatic EGFR-expressing NSCLC without driver mutations and for NSCLC with EGFR kinase domain mutations, both scheduled for June 2, 2025 [2] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer through its proprietary innate cell engagers (ICE) [4] - The company is headquartered in Mannheim, Germany, and aims to provide innovative therapies that enable tumor-targeted approaches to treat various hematologic and solid tumors [4]